Skip to main content
. 2021 Feb 27;9(3):198. doi: 10.3390/vaccines9030198

Figure 4.

Figure 4

Antibody-mediated prevention of mucosal HIV-1 infection in CD34T+ mice. (A) Schematic representation of the experimental design. CD34T+ control mice were given high dose i.r. challenges with NL4-3YU2 HIV-1 on consecutive days, whereas, the CD34T+ tri-mix mice additionally received i.p. injection of 2 mg each of 3BNC117, 10-1074 and SF12 one day before the 1st HIV-1 challenge. (B) Plasma HIV-1 RNA levels over time in the control and tri-mix mice. The lower black dotted line represents the assay quantification limit of 384 HIV-1 RNA copies/mL plasma. The right Y-axis for the tri-mix mice shows mean (N= 5) neutralizing antibody tri-mix levels in plasma over time. The upper grey dotted line represents the limit of detection of the antibody measurement assay. (C) Kaplan-Meier curve depicting rate of protection from mucosal HIV-1 infection in control and tri-mix mice from (B) statistical analysis done with Log-rank (Mantel-Cox) test. i.r. intra-rectal.